The Cheapest Way to Get GLP-1 in 2026: Every Option Ranked

The cheapest way to get GLP-1 medication in 2026 depends on which lane you actually qualify for. If you meet patient-assistance rules, the cheapest verified path is $0. If your insurance is usable, the cheapest practical route is often a low-fee prescribing program plus a $25 manufacturer-savings fill or ordinary plan copay. If you are paying cash and want the cleanest brand-name pricing, Zepbound is the most transparent self-pay option I verified at $299 to $449 per month by dose. ^{[3] [4] [5] [6]}

The hard part is that cheap GLP-1 access is full of false comparisons. A number can look low because it is only an intro month. It can look low because the membership fee excludes medication. It can look low because the product is compounded rather than FDA-approved. Or it can look low because the site never tells you the actual dose well enough to compare it honestly.

This guide is built for the reader who wants the real decision tree, not a soft-focus roundup. If you want the surrounding context first, open our telehealth comparison, insurance guide, Medicare coverage guide, and brand vs. compounded guide.

The Ranking at a Glance

If you want the short answer first:

1. Cheapest if you qualify: Novo Nordisk PAP at $0, but only for eligible patients and not for private-commercial-insurance holders. ^[3]
2. Cheapest if you already have usable coverage: manufacturer savings plus insurance can push Wegovy or Ozempic to $25 per month for eligible commercially insured patients. ^{[4] [5]}
3. Cheapest insurance-first telehealth path: Found markets insurance-linked memberships starting at $17 per month, with copays, coinsurance, and deductibles still applying. ^[9]
4. Cheapest transparent self-pay brand path: Zepbound at $299 for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg to 15 mg. ^[6]
5. Cheapest discount-card or cash-platform brand path: GoodRx currently shows Wegovy tablet pricing starting at $149 for selected lower strengths and other Wegovy offers starting at $199, but the deal changes by dose and offer window. ^[7]
6. Cheapest medication-included low-dose bundle I could verify: Noom Microdose GLP-1 starts at $79 for the initial 4 weeks and normalizes to $199 per month, but that is not the same thing as a full-dose FDA-approved brand path. ^[11]
7. Cheapest route people ask about but should not romanticize: international import or mail-order. FDA says importing drugs for personal use is illegal in most circumstances, with only narrow discretionary exceptions. ^[2]

Master Cost Comparison Table

Option	Monthly cost I verified	Biggest barriers	Timeline	Reliability
Patient assistance program	$0 if you qualify. [3]	Income limits, insurance rules, paperwork, not open to private commercial insurance.	Slowest start because application and approval come first.	High if approved, but narrow eligibility.
Insurance + manufacturer savings	As low as $25/month for eligible commercially insured Wegovy or Ozempic fills. [4] [5]	Only for eligible commercially insured patients; government beneficiaries excluded.	Fast if your plan already covers the drug and the card works.	High when the claim pays, but plan-dependent.
Insurance-linked telehealth	Found starts at $17/month plus your copay; Found says copay is typically around $30 for most members. [9] [10]	Coverage still depends on your insurer, deductible, and prior auth outcome.	Usually faster than a local-office search, slower than pure cash pay.	High if you want help navigating coverage, but not always cheapest after cost sharing.
Discount card / cash platform	GoodRx currently shows Wegovy offers starting around $149 to $199 depending on version and dose. [7]	Offer windows, dose restrictions, and pharmacy routing can change.	Fast if you are paying cash and can fill immediately.	Medium: useful, but more promotional and less stable than Lilly’s published Zepbound ladder.
Self-pay brand direct pricing	Zepbound $299 to $449/month by dose. [6]	Still expensive if uninsured; prescription required.	Usually the cleanest fast-start cash option.	High because the public price ladder is unusually transparent.
Telehealth cash-pay bundle	Ro membership $45 first month, then $145/month, with medication billed separately; Noom GLP-1 Rx starts at $129 then $279/month with medication included; Calibrate starts at $199/month with a 3-month commitment. [8] [11] [12]	You have to separate membership cost from medication cost.	Often quick, but intake and PA work still take time.	Medium to high, depending on whether the medication model is clear.
Compounded or microdose alternatives	Sometimes lower than brand starter pricing, including Noom Microdose at $79 initially. [11]	Product type may differ from a full-dose FDA-approved brand path; compounding adds quality and safety concerns.	Often marketed as fast.	Lower, because the cheap number may hide a different product or risk profile. [1]
Clinical trials	Sometimes low-cost or no-cost for the study intervention, but costs vary by protocol. [13] [14]	Eligibility, geography, consent, and uncertainty about what the study covers.	Slowest and most selective path.	Medium for access, low for convenience.
International or mail-order import	Sticker price can look low, but it is not a dependable legal shortcut. [2]	FDA import restrictions, customs risk, and source-quality risk.	Unpredictable.	Low.

Path-by-Path Breakdown

1. Insurance-covered access is still the best bargain when it actually works

If your plan already covers the drug, the cheapest move is usually to stay inside that lane and add official savings on top. Wegovy’s current page says eligible commercially insured patients can pay as little as $25 per month, and Ozempic’s savings page says the same. ^{[4] [5]}

That does not mean every insured person pays $25. It means your final bill depends on three separate gates:

• whether the plan covers obesity treatment at all
• whether prior authorization is approved
• whether you meet the card’s commercial-insurance rules

That is why a bland sentence like “use insurance first” is incomplete. Insurance is cheapest when the plan is already friendly. It is frustrating and slow when the benefit is excluded or the deductible is still biting.

2. Manufacturer savings are real, but they are not universal

The manufacturer-card math is straightforward only for a narrow group of patients.

• Wegovy: eligible commercially insured patients can pay as little as $25 per month. Self-pay pricing also starts at $149 for some Wegovy pill doses and $199 for some pen offers. ^[4]
• Ozempic: eligible commercially insured patients can pay as little as $25, while self-pay offers currently range from $199 intro pricing to $349 or $499 depending on dose and offer status. ^[5]
• Zepbound: Lilly’s self-pay ladder is more transparent than most of the market, which is why it is the cleanest cash benchmark even when the headline number is higher than a temporary promo. ^[6]

The practical rule is simple: if a price only exists inside a savings-card eligibility box, do not treat it as a public market price.

3. GoodRx and discount-card pricing can be useful, but it is not the same as stable long-term pricing

GoodRx is worth checking because it sometimes turns brand pricing into something much closer to telehealth-bundle pricing. Its current Wegovy page shows tablet pricing starting at $149 for lower strengths, higher-strength tablet pricing around $299, and some Wegovy pen offers around $199 to start. ^[7]

That can be a legitimate cheap path for a self-pay reader, but four caveats matter:

• the price can be tied to a specific dose
• it can be tied to an offer window
• it may route through a specific fulfillment or prescriber flow
• it does not mean every pharmacy quote or future refill will match the teaser price

So yes, discount-card and platform pricing belong in the ranking. They just should not be confused with a fixed long-term treatment cost.

4. Telehealth prices only make sense when you split the membership fee from the medication fee

This is where a lot of “cheapest GLP-1” articles fall apart.

• Ro: the Body membership is $45 for the first month and $145/month ongoing, with medication charged separately. Ro also says its cash-pay GLP-1 options start at $149/month and that it matches the lowest published manufacturer cash pricing. ^[8]
• Found: insurance-linked memberships start at $17/month, and Found says members using insurance typically still have a copay around $30, though exact cost varies by deductible and plan. ^{[9] [10]}
• Noom: the full-dose GLP-1 Rx program starts at $129 for the first 4 weeks and $279/month after; the Microdose program starts at $79 and then $199/month. ^[11]
• Calibrate: the Metabolic Reset starts at $199/month with a 3-month commitment, while the company says GLP-1s for most commercially insured members should be $25/month or less after any deductible is met. ^[12]

The right comparison is never just “membership A vs membership B.” The right comparison is:

membership fee + medication fee + whether the product is full-dose FDA-approved brand medication + how much friction you are paying to avoid

5. Compounded and low-dose alternatives can be cheaper, but the cheap number is not the whole story

Some of the lowest sticker prices in this market come from paths that are not apples-to-apples with brand medication. FDA says compounded GLP-1 drugs are not FDA-approved, do not go through premarket review for safety, effectiveness, or quality, and should not be treated like interchangeable copies of the approved brands. FDA has also warned about dosing errors, warm-shipped product, and ingredient-quality concerns. ^[1]

That does not make every low-cost alternative automatically wrong. It does mean you should separate two questions:

1. Is this the cheapest number on the page?
2. Is this the same product, oversight level, and risk profile as the brand medication I think I am comparing it to?

If the answer to question 2 is no, the comparison needs a warning label.

6. Clinical trials are a real path, but not a fast or universal one

Clinical trials belong on this list because they can reduce or eliminate some treatment costs, and they can include close research follow-up. But they are not a generic discount program.

NIH says clinical trials can involve extra care and attention from the trial staff, and it explicitly tells participants to ask what they may have to pay as part of the study. ^[13] ClinicalTrials.gov study pages are useful because they show the actual protocol, eligibility rules, and locations. In the STEP 7 semaglutide obesity study listing, participants were randomized to semaglutide or placebo and also received counseling on healthy food choices and physical activity. ^[14]

The honest framing is:

• this path can be low-cost or no-cost for some participants
• it can also involve screening failures, travel, and time burden
• what is covered depends on the protocol, not wishful thinking

7. International or mail-order import is not a dependable cheap workaround

This is the path readers ask about when U.S. prices feel absurd. FDA’s current position is still blunt: in most circumstances, it is illegal for individuals to import drugs into the U.S. for personal use. The agency describes only narrow situations where personnel may exercise discretion, such as a serious condition with no effective domestic commercial or clinical option, written personal-use affirmation, and generally no more than a three-month supply. ^[2]

That means international mail-order is not a stable cheap-access strategy. It is a legal and logistics risk with a much weaker reliability profile than the headline price suggests.

Quick Decision Tree

Use this if you need a next step, not another article:

1. Do you qualify for patient assistance? Check PAP first because nothing beats $0. ^[3]
2. Do you have commercial insurance? Check official Wegovy or Ozempic savings next and see whether your plan already covers the drug. ^{[4] [5]}
3. Do you want help fighting for coverage? Compare insurance-first programs such as Found, Ro, or Calibrate. ^{[8] [9] [12]}
4. Do you need a self-pay brand option with clean public pricing? Compare Zepbound first, then dose-specific Wegovy or GoodRx offers. ^{[4] [6] [7]}
5. Are you looking at a very low price that depends on compounding, microdosing, or foreign import? Stop and check the product type, the exact dose, and the legal or safety tradeoff before you treat that number as equivalent. ^{[1] [2]}

Real-World Cost Scenarios

These are the situations most readers actually fall into.

Scenario 1: You have good commercial coverage

The cheapest realistic path is often a low-fee insurance-navigation program plus an ordinary plan copay or a savings-card fill. Found’s current public math can start at $17/month for the membership plus a typical copay around $30. In plain English, that can land around the high double digits per month, not hundreds. ^{[9] [10]}

Scenario 2: You have coverage, but the deductible or prior auth process is the problem

This is where “insurance” stops feeling cheap. The membership fee may still be low, but the pharmacy price can stay high until the deductible is met or the PA clears. Calibrate is unusually direct here: the program costs $199/month, and the medication gets cheap only after the deductible math is out of the way. ^[12]

Scenario 3: You are uninsured and want the cheapest full-brand path

Start with the cleanest published self-pay ladder, not the prettiest ad. Today that is Zepbound at $299 to $449/month depending on dose. GoodRx and selected Wegovy offers can beat that on some starter-dose promos, but Zepbound is still the easiest long-term self-pay brand price to understand. ^{[4] [6] [7]}

Scenario 4: You are uninsured and only need the lowest sticker price

That is the lane where microdose bundles, discount-card promos, or trial screening may look best on paper. Noom’s Microdose GLP-1 program starts at $79 and then normalizes to $199/month. That can be a legitimate low-cost starting point, but it is not the same thing as a full-dose FDA-approved brand comparison. ^[11]

Where Cheap Gets Dangerous

The market has two big cheap-price traps.

Trap 1: Treating compounded GLP-1 as interchangeable with brand medication

FDA’s warning page is clear enough that this should never be hand-waved away. If the low price depends on compounded GLP-1, you are not comparing equal products. ^[1]

Trap 2: Treating foreign import as a routine workaround

The FDA import page makes the legal position clear: this is not a normal, dependable consumer access strategy in the U.S. ^[2]

The useful rule is:

A cheap price is good only if you can explain what exact product it buys, how you will keep getting it, and what risk you accepted to get there.

Bottom Line

If you want the cleanest one-sentence answer, it is this:

The cheapest verified GLP-1 path in 2026 is $0 through patient assistance if you qualify, the cheapest insurance-backed path is usually savings-card or low-copay coverage, and the cheapest transparent self-pay brand route is Zepbound at $299 to $449 per month by dose.

The more important answer is that “cheap” only helps if the comparison is honest. A $25 savings-card fill, a $17 insurance-navigation membership, a $149 starter-dose GoodRx offer, a $79 microdose bundle, and a $299 self-pay brand prescription are all different things. They solve different problems and carry different tradeoffs.

If you want more pricing breakdowns like this, join the newsletter. We track the manufacturer-price changes, telehealth-model shifts, and coverage updates that actually change what people pay.

Last reviewed: April 24, 2026